Biotech stories

OpenAI expands its enterprise AI push with a biology-focused model aimed at speeding target discovery, analysis and early drug development.

US AI megadeals push global venture capital to a record USD $330.9 billion as OpenAI, Anthropic and xAI dominate first-quarter funding.

ACTO rolls out role-based AI SuperAgents for life sciences field teams, aiming to speed compliant access to approved content across sales and medical work.

Iran-linked wiper cyber attack cripples Stryker plants, disrupting implant production and locking thousands of staff out of global networks.

Biotech's next leaders will be defined less by scientific breakthroughs and more by diverse teams building resilient clinical infrastructure.

Belfast tech firm SciLeads will create 60 fully remote roles over three years as it scales its life sciences market intelligence platform.

Anthropic rolls out Claude for Healthcare and Life Sciences, adding sector-specific connectors, agent skills and consumer health integrations.

Perforce CTO Rod Cope predicts context and agentic AI will transform coding, jobs and security as ambient systems quietly permeate daily life.

Nebius Group has raised USD $4.3 billion to enhance its AI infrastructure and support expansion into Asia, focusing on biotech and drug discovery.

Biostate AI's K-Dense Beta, an AI research system, slashes biological research times from years to weeks, proven through Harvard Medical School longevity studies.

Swiss Deep Tech startups have surpassed USD $100 billion in value, boosted by strong venture capital and academic innovation in AI, biotech, and space sectors.

Atturra has secured the acquisition of Project Delivery Services LLC, known as Kitepipe, for USD $3.15 million, enhancing its Boomi service capabilities.

The UK-APAC Tech Growth Programme has successfully arranged over 40 meetings for six UK tech firms with leading South Korean businesses, promoting semiconductor and AI innovations.

Danish biotech firm Fuse Vectors has secured USD $5.2 million in pre-seed funding to advance its innovative cell-free gene therapy technology.

Kyriba's latest CIR unveils a $30bn FX impact on 1,200 multinational firms in Q3 2023, highlighting FX's influence on revenues and cash flows.

The high content screening market will register positive growth, with the overall valuation forecast to reach US$1.6 billion in 2022, according to FMI.